September 19, 2019 / 7:03 AM / a month ago

BRIEF-AroCell: TK1 Can Be Used For Early Detection Of Therapy Response In Breast Cancer Treatment

Sept 19 (Reuters) - AroCell AB:

* SAID ON WEDNESDAY THYMIDINE KINASE 1 CAN BE USED FOR EARLY DETECTION OF THERAPY RESPONSE IN BREAST CANCER TREATMENT

* RESULTS SHOW THAT A TK1-BASED CELL-LOSS METRIC AFTER TWO CYCLES OF THERAPY PREDICTED THE STATUS AT THE OPERATION AFTER SIX CYCLES OF CHEMOTHERAPY

* CONCENTRATION OF TK1 IN BLOOD WAS MEASURED WITH TK 210 ELISA

* STUDY CONCLUDES THAT TK1 HAS THE POTENTIAL TO BE OF GREAT VALUE FOR EARLY PREDICTION ON RESPONSE OF CYTOSTATIC TREATMENT FOR PATIENTS WITH BREAST CANCER

Source text for Eikon:

Further company coverage:

Gdynia Newsroom

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below